Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

☆한국어

Y-Biologics, Inc

와이바이오로직스338840KOSDAQSector: Pharma & Biotech
₩8,4601.86%Market cap ₩130.3BAs of Sep 3, 2026 close · updated once daily
Market cap
₩130.3B
#572 in KOSDAQ
Loss
PER not computable
5.03x
Sector median 1.61x
0.0%
Sector median 0.0%
D
Grade D26 ptsBottom 10% of 2,523 graded stocksMethodology v2.0
Financial strength
35.4/100
Growth momentum
21.0/100
Price attractiveness
17.2/100
Shareholder Return
37.5/100

As of Sep 3, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

How to read this grade
SABCDCurrentF

Toward S means a higher total-score band; toward F, a lower band. Badges are distinguished by ink intensity and shape (fill, outline, dashed) — never by hue.

Maegim maps a total score — built from sector-relative percentile scoring — onto fixed, predefined thresholds to assign one of six bands, S to F. This stock is scored by the same formula as all 2,523 graded stocks and is currently in band D with a total score of 26 points.

How grades are computed →What grades do and don’t mean →What the grade does not reflect →

Position within sector

Mechanically selected indicators in the top or bottom 30% of sector percentiles · among 250 stocks in Pharma & Biotech

1-year closing price

Loading closing price history…
 
Low ₩7,520High ₩35,600
Latest close
Price change by period
1W
6.10%
1M
6.00%
3M
47.20%
1Y
34.10%

As of the Sep 3, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

35.4/100
How much debt does it carry relative to equity?
109.8%
Sector median 51.6%
Sector lowhighBottom 22.5% in sector
Can it cover what's due within a year?
3616.1%
Sector median 191.7%
Sector lowhighTop 1.4% in sector
How much of revenue becomes profit?
-318.2%
Sector median -2.4%
Sector lowhighBottom 15.4% in sector
How much did it earn on its own capital?
-158.0%
Sector median -4.5%
Sector lowhighBottom 5.1% in sector

Source filing: annual report (separate) — view original ↗

2

Growth momentum

21.0/100
How much did revenue grow in a year?
-49.5%
Sector median 6.4%
Sector lowhighBottom 4.8% in sector
Did core profits grow in a year?
-9.7%
Sector median 3.6%
Sector lowhighBottom 37.1% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

17.2/100
Is the price expensive relative to earnings?
Loss-making (P/E not computable)
Sector median P/E of profitable peers 16.3x · 58% loss-making
Sector lowhighBottom 9.5% in sector
Is the price expensive relative to book value?
5.03x
Sector median 1.61x
Sector lowhighBottom 24.9% in sector

Valuation uses the Sep 3, 2026 close and market cap

4

Shareholder Return

Single-indicator axis37.5/100
Does the company actually pay dividends?
0.0%
Sector median 0.0%
Sector lowhighBottom 37.5% in sector

Source filing: annual report (separate) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 2, 2026

Of 9 items: 2 met · 7 not met · 0 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Not met
-₩42B
Positive operating cash flow
Whether cash flow from operations is above zero.
Not met
-₩5.8B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Not met
-21.3% → -193.4%
Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Met
-₩5.8B vs -₩42B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Not met
15.5% → 52.3%
Current ratio up
Whether current assets over current liabilities rose from the prior year.
Met
510.3% → 3616.1%
Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Not met
14,782,516 → 15,178,081
Operating margin up
Whether operating income over revenue rose from the prior year.
Not met
-146.6% → -318.2%
Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Not met
0.19x → 0.13x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (separate) — view original ↗

Grade change history

Jul 23, 2026D

Methodology version change (v2.0 applied)

Jul 15, 2026DVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Disclosure & financial badges

Factual records determined from public filings and periodic reports by fixed rules — not buy/sell signals.

Negative-evidence group (dilution, loss, dispute)Mixed interpretationPositive-evidence group (shareholder return)Dots classify the disclosure type by the direction of research evidence — not an assessment or investment judgment about this company.

Disclosure event history

CB with conversion-price adjustment clause (past 36 months)

1 convertible bond (CB) issuance resolutions including a downward conversion-price adjustment (refixing) clause were disclosed in the past 36 months (latest filing 2025-12-30). View filing ↗

Financial fact combinations

Operating losses for 3 consecutive fiscal years

Recorded operating losses in three consecutive fiscal years, FY2023–FY2025 (per annual reports).

Determined as of 2026-09-02

Recent filings for this stock

Last 120 days · monitored filing types only
Periodic report filedAug 14, 2026Source ↗
CEO changeJul 3, 2026Source ↗
Periodic report filedMay 15, 2026Source ↗

View in the filings calendar →